Kura Oncology Inc (KURA) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...

Kura Oncology to Participate in Cantor Global Healthcare Conference

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kura Oncology Reports Second Quarter 2024 Financial Results

– Topline data from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025 –...

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

– Preclinical data suggest combination of ziftomenib and imatinib has potential to resensitize patients to...

Kura Oncology to Report Second Quarter 2024 Financial Results

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a...

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report